%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 15 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 13 0 R /GS2 14 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260413092534+00'00') /ModDate (D:20260413092534+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 11 0 R ] /Contents 7 0 R >> endobj 7 0 obj << /Length 5226 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces Fast Track Designation)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Granted by the FDA to CFI-402257 for the Treatment of)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(ER+/HER2- Breast Cancer)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(NEW YORK, Jan. 10, 2023 /PRNewswire/ ?? Treadwell Therapeutics, a clinical-stage biotechnology)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(company, announced today that the U.S. Food and Drug Administration \(FDA\) has granted Fast Track)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(Designation to CFI-402257, a best in class inhibitor of Threonine Tyrosine Kinase \(TTK, also known as)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(Mps1\), for the treatment of adult patients with ER+/HER2- advanced breast cancer after disease)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(progression on prior CDK4/6 inhibitors and endocrine therapy, both as a monotherapy and in)] TJ ET BT 35.000 595.757 Td /F1 12.0 Tf [(combination with fulvestrant.)] TJ ET BT 35.000 569.105 Td /F1 12.0 Tf [(??There is an urgent need for new, safe and efficacious therapies to treat ER+/HER2- breast cancer,)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(particularly when standard of care regimens fail,?)] TJ ET BT 303.104 554.453 Td /F1 12.0 Tf [()] TJ ET BT 306.440 554.453 Td /F1 12.0 Tf [( said Dr. Mark Bray, Treadwell CSO and Co-)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(founder. ??CFI-402257 has shown early signs of durable activity with a manageable safety profile, as)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(a monotherapy and in combination with fulvestrant in ER+/HER2- breast cancer patients that have)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(failed CDK4/6 inhibitors. We are thankful for the Fast Track Designation granted by the FDA and look)] TJ ET BT 35.000 495.845 Td /F1 12.0 Tf [(forward to the continued development of CFI-402257 in ER+/HER2- breast cancer.?)] TJ ET BT 487.544 495.845 Td /F1 12.0 Tf [()] TJ ET BT 35.000 469.193 Td /F1 12.0 Tf [(Fast Track designation seeks to streamline the development and accelerate the review of new agents)] TJ ET BT 35.000 454.541 Td /F1 12.0 Tf [(with potential to treat serious or life-threatening diseases and that potentially address an unmet medical)] TJ ET BT 35.000 439.889 Td /F1 12.0 Tf [(need. Drugs that are granted this designation can have more frequent interactions with the FDA, as well)] TJ ET BT 35.000 425.237 Td /F1 12.0 Tf [(as potential pathways for expedited approval.)] TJ ET BT 35.000 394.552 Td /F3 14.0 Tf [(About ER+/Her2- Breast Cancer)] TJ ET BT 35.000 365.362 Td /F1 12.0 Tf [(Globally, breast cancer is the world??s most prevalent cancer and the 2nd leading cause of cancer)] TJ ET BT 35.000 350.710 Td /F1 12.0 Tf [(death in women in many countries. The ER+/HER2- subtype is the most common subtype of breast)] TJ ET BT 35.000 336.058 Td /F1 12.0 Tf [(cancer, accounting for 68% of all breast cancer types, with nearly 1.2 million women living with the)] TJ ET BT 35.000 321.406 Td /F1 12.0 Tf [(disease in the US alone. Standard of care for ER+ patients is CDK4/6 inhibitors in combination with)] TJ ET BT 35.000 306.754 Td /F1 12.0 Tf [(endocrine therapies, which have been very successful in prolonging survival for this patient population.)] TJ ET BT 35.000 292.102 Td /F1 12.0 Tf [(However, resistance to this treatment occurs within a median of 2 years. As a result, the ER+)] TJ ET BT 35.000 277.450 Td /F1 12.0 Tf [(population resistant to this standard of care is growing and is an unmet medical need requiring new)] TJ ET BT 35.000 262.798 Td /F1 12.0 Tf [(treatment options.)] TJ ET BT 35.000 232.114 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 202.923 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 188.271 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 173.619 Td /F1 12.0 Tf [(The Company??s internally developed clinical pipeline includes CFI-400945, CFI-402257 \(TTK)] TJ ET BT 35.000 158.967 Td /F1 12.0 Tf [(inhibitor\) and CFI-402411 \(HPK1 inhibitor\). The company is also advancing a pre-clinical pipeline of)] TJ ET BT 35.000 144.315 Td /F1 12.0 Tf [(first-in-class antibody and TCR-based cell therapy assets. For more information, please visit)] TJ ET 0.000 0.000 0.800 rg BT 35.000 129.663 Td /F1 12.0 Tf [(www.treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 35.000 127.053 m 147.680 127.053 l S 0.000 0.000 0.000 rg BT 147.680 129.663 Td /F1 12.0 Tf [(.)] TJ ET BT 35.000 98.979 Td /F3 14.0 Tf [(Contact)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /Annot /Subtype /Link /F 28 /A 12 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 127.3324 147.6800 139.5424 ] >> endobj 12 0 obj << /Type /Action /S /URI /URI (https://treadwelltx.com/) >> endobj 13 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 14 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 15 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 17 0 R 19 0 R ] /Contents 16 0 R >> endobj 16 0 obj << /Length 1165 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 817.558 m 87.020 817.558 l S 0.000 0.000 0.800 rg BT 35.000 805.516 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 802.906 m 137.192 802.906 l S 0.000 0.000 0.000 rg BT 35.000 778.864 Td /F1 12.0 Tf [(General inquiries:)] TJ ET 0.000 0.000 0.000 RG 35.000 776.254 m 129.032 776.254 l S 0.000 0.000 0.800 rg BT 35.000 764.212 Td /F1 12.0 Tf [(info@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 761.602 m 149.876 761.602 l S 0.000 0.000 0.000 rg BT 35.000 737.560 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 722.908 Td /F1 12.0 Tf [(January 10, 2023)] TJ ET q 35.000 719.978 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 803.1854 137.1920 815.3954 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj 19 0 obj << /Type /Annot /Subtype /Link /F 28 /A 20 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 761.8814 149.8760 774.0914 ] >> endobj 20 0 obj << /Type /Action /S /URI /URI (mailto:info@treadwelltx.com%C2%A0) >> endobj xref 0 21 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000644 00000 n 0000005922 00000 n 0000006029 00000 n 0000006138 00000 n 0000006251 00000 n 0000006384 00000 n 0000006460 00000 n 0000006517 00000 n 0000006574 00000 n 0000006705 00000 n 0000007923 00000 n 0000008056 00000 n 0000008133 00000 n 0000008266 00000 n trailer << /Size 21 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 8351 %%EOF